Lyell Immunopharma, Inc. (LYEL) Stock Price & Analysis
Lyell Immunopharma, Inc. (LYEL) is trading at USD 16, up 3.76% today, as of November 10, 2026 at 16:30 UTC (US market open; quotes may be delayed), according to Nexqual market data.
LYEL last closed at USD 15.42; today's session has ranged USD 14.92–16.51 on volume of 81,288 shares. Market capitalization is $393.37M, with a 52-week range of USD 7.2–45 (NMS). Source: Nexqual, retrieved November 10, 2026 at 16:31 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LYEL.md
Key facts (LYEL)
- Last four reported quarters (through Sep 30, 2026): revenue $15K, net income -$255M (-1701066.7% margin), free cash flow -$140M (SEC filings).
- Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 38.38 (range 12–49).
- Total return with dividends: 1Y -9.5% vs S&P 500 +10.9%; 5Y -93.0% vs S&P 500 +71.1%.
- Latest earnings report: 2026-11-04 (next date not yet announced).
- Dividend: LYEL paid no cash dividend in the last five years.
- Short interest: 6.64% of float (as of 2026-10-15), 7.9 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LYEL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.7M | $84.7M | $130K | $61K | $36K | $15K |
| Operating income | -$215M | -$187M | -$247M | -$359M | -$269M | -$268M |
| Net income | -$250M | -$183M | -$235M | -$343M | -$274M | -$255M |
| EPS (diluted) | -$36.80 | -$14.80 | -$18.70 | -$26.23 | -$16.06 | — |
| Free cash flow | -$192M | -$194M | -$166M | -$163M | -$151M | -$140M |
| Operating margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -748344.4% | -1783580.0% |
| Net margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% | -1701066.7% |
| Revenue growth | +37.3% | +695.1% | -99.8% | -53.1% | -41.0% | — |
| Cash + short-term investments | $615M | $640M | $546M | $371M | $247M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (LYEL)
P/S 26224.6x · P/B 2.0x · FCF yield -35.58% · Earnings yield -64.87%
Analysts (LYEL)
Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 38.38 (low 12, high 49).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-03 | Needham | Reiterated | Buy | $44 |
| 2026-09-11 | Needham | Reiterated | Buy | $44 |
| 2026-08-06 | Stifel | Initiated | Buy | $36 |
| 2026-07-22 | B. Riley Securities | Initiated | Buy | $44 |
Total return (dividends reinvested) (LYEL)
| 1Y (from 2025-11-10) | 5Y (from 2021-11-08) | |
|---|---|---|
| Total return | -9.5% | -93.0% |
| S&P 500 (SPY) | +10.9% | +71.1% |
| Per year | -9.5% | -41.2% |
| Volatility (annualized) | 87.6% | 90.4% |
| Max drawdown | -80.5% (Dec 2025→Oct 2026) | -96.5% (Nov 2021→May 2025) |
Dividends (LYEL)
LYEL paid no cash dividend in the last five years.
Short interest (LYEL)
1,398,232 shares sold short, 6.64% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 1,187,902 shares (+17.7%). Days to cover: 7.9 (short shares ÷ average daily volume).
LYEL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$1.69 | −$1.88 | Beat +10.1% | — |
| — | Quarter ended Jun 30, 2026 | −$1.74 | −$1.79 | Beat +2.8% | — |
| — | Quarter ended Mar 31, 2026 | −$1.10 | −$2.36 | Beat +53.4% | — |
| — | Quarter ended Dec 31, 2025 | −$7.68 | −$2.23 | Miss −244.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
LYEL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 4, 2026 | 8-K | Quarterly results |
| Nov 4, 2026 | 8-K | Unregistered sale of shares |
| Sep 10, 2026 | 8-K | Other material event “On September 10, 2026, Lyell Immunopharma, Inc. (the "Company") issued a press release (the "LYL273 Press Release") regarding the completion of the technology transfer for LYL273 to the Company's LyFE Manufacturing Facility in Bothell, Washington and an updated timeline on the Phase 1/2 trial evaluating LYL273 in metastatic colorectal cancer. LYL273 is the Company's next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate for the treatment of relapsed/refractory metastatic colorectal cancer…” |
| Aug 14, 2026 | Schedule 13G/A | Foresite Capital Fund IV, L.P., Foresite Capital Management IV, LLC: 2.7% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LYEL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-1.61 | $0.00 | −$1.61 | $0 | 1 |
| Next quarter (ends Mar 2027) | $-1.82 | $-2.13 | +$0.31 | $5,000 | 5 |
| Current fiscal year (ends Dec 2026) | $-6.92 | $0.00 | −$6.92 | $6,400 | 1 |
| Next fiscal year (ends Dec 2027) | $-6.32 | $0.00 | −$6.32 | $0 | 1 |
LYEL options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 10 | 202.5% | ±21.4% |
| Dec 18, 2026 | 38 | 127.3% | ±32.4% |
| Jan 15, 2027 | 66 | 99.5% | ±61.9% |
| Apr 16, 2027 | 157 | 89.0% | ±44.4% |
30-day implied volatility 108.9% vs 124.6% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 10, 2026 at 16:31 UTC)
| Price | USD 16 |
|---|---|
| Change | ▲ 3.76% (up) |
| Previous Close | USD 15.42 |
| Open | USD 15.17 |
| Day Range | USD 14.92 – 16.51 |
| 52-Week Range | USD 7.2 – 45 |
| Volume | 81,288 shares |
| Market Cap | $393.37M |
| Exchange | NMS |
Technical Analysis (LYEL)
Nexqual's technical model rates LYEL "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of November 10, 2026 at 16:31 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 78.83 (overbought) |
| vs SMA50 | Above (USD 10.91) |
| MACD | 1.4 (positive) |
Analyst Ratings (LYEL)
Wall Street analysts rate LYEL "Buy" based on 8 analysts, with a mean price target of USD 38.38 (range USD 12–49), per Nexqual as of November 10, 2026 at 16:31 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 38.38 |
| High Target | USD 49 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 7 / 0 / 1 |
Earnings (LYEL)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -1.61 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -1.69 vs est -1.88 ▲ beat |
| 2026-06-30 | USD -1.74 vs est -1.79 ▲ beat |
| 2026-03-31 | USD -1.1 vs est -2.36 ▲ beat |
| 2025-12-31 | USD -7.68 vs est -2.23 ▼ miss |
Source: Nexqual, November 10, 2026 at 16:31 UTC.
Financials & Fundamentals (LYEL)
| Total Revenue | $15,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -80.00% |
| Gross Margin | +100.00% |
| Operating Margin | -1609833.40% |
| Profit Margin | +0.00% |
| ROE | -97.79% |
| Debt / Equity | 0.23 |
| Current Ratio | 4.02 |
| Total Cash | $177.11M |
| Total Debt | $44.28M |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | -$139.97M (-933100.0% of revenue) |
Source: Nexqual, November 10, 2026 at 16:31 UTC.
Financial Health Score (LYEL)
Nexqual rates Lyell Immunopharma, Inc.'s overall financial health "Weak" across five dimensions, as of November 10, 2026 at 16:31 UTC.
| Growth | Critical — Revenue -63% (last 4 quarters to Sep 2026 vs the 4 before, SEC), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $177M cash vs $44M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$140M (last 4 quarters to Sep 2026, SEC), burning cash |
| Efficiency | Critical — ROE -132%, ROA -93.2% (last 4 quarters, SEC) |
Ownership (LYEL)
| Insider Ownership | +28.63% |
|---|---|
| Institutional Ownership | +48.91% |
| Shares Outstanding | 24.59M |
| Float | 9.89M |
| Short % of Float | +6.64% |
Source: Nexqual, November 10, 2026 at 16:31 UTC.
Leadership (LYEL)
Lyell Immunopharma, Inc. is led by Lynn Seely, Principal Executive Officer, President, CEO & Director, per Nexqual as of November 10, 2026 at 16:31 UTC.
| Principal Executive Officer, President, CEO & Director | Lynn Seely |
|---|---|
| Founder & Executive Chairman | Richard D. Klausner |
| Chief Operating Officer | Stephen J. Hill |
| Chief Scientific Officer | Gary K. Lee |
| Principal Financial Officer, CFO & Chief Business Officer | Smital Shah |
Major Backers & Investors (LYEL)
Notable institutional backers of Lyell Immunopharma, Inc. include Arch Venture Management, Llc, GSK plc, Orland Properties Ltd., according to Nexqual as of November 10, 2026 at 16:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Arch Venture Management, Llc | 13.21% |
| GSK plc | 6.15% |
| Orland Properties Ltd. | 3.07% |
| Decheng Capital LLC | 2.81% |
| Almitas Capital LLC | 2.36% |
| Foresite Capital Management V, LLC | 1.94% |
| Millennium Management | 1.49% |
| Opaleye Management Inc. | 1.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.2% |
| BlackRock | 2.95% |
Source: Nexqual, November 10, 2026 at 16:31 UTC.
From Lyell Immunopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our research scientists are also developing next-generation CAR T-cell product candidates for additional solid tumor indications enhanced with our anti-exhaustion and additional arming technologies and manufactured with our proprietary protocols.
- We continue to invest in earlier stage cell therapy research and development utilizing our proprietary technologies.
- Epi‑R is our proprietary ex vivo manufacturing protocol that is designed to generate populations of stemlike T cells with reduced exhaustion and improved proliferation and antitumor activity.
- Our nonclinical research activities explore stacking our proprietary anti-exhaustion technologies with these additional approaches via the expression of novel chimeric proteins and vector design to generate fully-armed CAR T-cell product candidates.
Legal & Regulatory Risks (Item 1A, quoted)
- Our cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in our ability to achieve regulatory approval, commercialization or payor coverage of our product candidates.
- We expect the novel nature of our product candidates to create challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T-cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.
- Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
- The FDA has granted Fast Track and RMAT designations to ronde-cel for the treatment of relapsed and/or refractory aggressive B‑cell lymphoma in the 3L+ settings, RMAT designation to ronde-cel for the treatment of LBCL in the 2L setting and granted Fast Track designation to LYL273 for the treatment of mCRC. We may seek additional designations for our product candidates or for ronde-cel or LYL273 in other indications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGON | CG Oncology, Inc. | USD 73.12 | ▼ 2.17% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | USD 48.24 | ▼ 2.03% |
| ORKA | Oruka Therapeutics, Inc. | USD 104.47 | ▼ 0.09% |
| AXSM | Axsome Therapeutics, Inc. | USD 136.77 | ▲ 2.1% |
| IMVT | Immunovant, Inc. | USD 35.47 | ▲ 0.91% |
| CAI | Caris Life Sciences, Inc. | USD 24.51 | ▼ 4.17% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 16:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt